Race Oncology announces deal with manufacturer Ardena to develop companys new IV formulation RC220

Race Oncology announces deal with manufacturer Ardena to develop companys new IV formulation RC220

–News Direct–

Race Oncology CEO Damian Clark-Bruce joined Steve Darling from Proactive to share significant news about the company's recent agreements and partnerships.

Firstly, Race Oncology has signed an agreement with Ardena Holding, a global contract development and manufacturing organization. This collaboration will provide additional Good Manufacturing Practice -standard manufacturing capability for its flagship IV formulation of bisantrene, RC220. Ardena is a fully integrated CDMO known for its expertise in assisting biopharma companies throughout the drug development life cycle, including the production of sterile injectable products for clinical development.

Clark-Bruce further explained to Proactive that this partnership with Ardena strengthens Race Oncology's existing manufacturing programs, as it establishes a primary source for EU-compliant supplies of RC220. This is particularly important for EU clinical studies, ensuring the availability of high-quality, GMP-compliant formulations of RC220.

Additionally, Clark-Bruce shared news about an exclusive license agreement with City of Hope, a prominent US cancer research and treatment organization. Through this agreement, Race Oncology gains access to City of Hope's intellectual property, which highlights bisantrene as a potent inhibitor of the human fat mass and obesity-associated protein. This discovery opens up new possibilities for exploring the therapeutic potential of bisantrene beyond its established use as an anti-cancer agent.

Contact Details

Proactive Investors

+1 604-688-8158


View source version on newsdirect.com: https://newsdirect.com/news/race-oncology-announces-deal-with-manufacturer-ardena-to-develop-companys-new-iv-formulation-rc220-160803941

Race Oncology Ltd

comtex tracking


Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No DigiShor journalist was involved in the writing and production of this article.